Ocifisertib
CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
Product Specifications
CAS Number
1338806-73-7
Product Name Alternative
CFI-400945 (free base)
UNSPSC
12352005
Target
Apoptosis; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CFI-400945-free-base.html
Concentration
10mM
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@]12[C@H](C3=CC4=C(C=C3)C(/C=C/C5=CC=C(CN6C[C@@H](C)O[C@@H](C)C6)C=C5)=NN4)C1)NC7=C2C=C(OC)C=C7
Molecular Formula
C33H34N4O3
Molecular Weight
534.65
References & Citations
[1]Sampson PB, et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S) .2- (3- ((E) .4- (((cis) .2,6-dimethylmorpholino) methyl) styryl) . 1H.indazol-6-yl) -5?'-methoxyspiro[cyclopropane-1,3?'-indolin]-2?'-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015 Jan 8;58 (1) :147-69.|[2]Mason JM, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26 (2) :163-76.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PLK4
Citation 01
Ir J Med Sci. 2023 Apr;192 (2) :561-567.|J Cancer Res Clin Oncol. 2020 Nov;146 (11) :2871-2883.|Nat Nanotechnol. 2021 Jul;16 (7) :830-839.|Int J Mol Med. 2021 Jan;47 (1) :151-160.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![[KO Validated] NDUFA7 Polyclonal Antibody](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
AMM14448V 100 µL
FBXO42 Mouse Monoclonal Antibody [Clone ID: LBI2G7]
Sign In for Pricing
View Details